生物标志物与聚焦超声:脑肿瘤液体活检的未来
本文综述了MRI引导聚焦超声(MRgFUS)用于脑肿瘤液体活检的概念与证据。通过低强度脉冲式MRgFUS短暂破坏血脑屏障,可能增强血液和脑脊液中脑肿瘤来源生物标志物的检测。目前尚无脑肿瘤来源生物标志物用于常规临床实践,该策略仍处于临床前和临床试验阶段。
要点
- 低强度脉冲式MRgFUS可短暂破坏血脑屏障,增强脑肿瘤生物标志物释放入血或脑脊液。
- 高强度MRgFUS可消融脑肿瘤,但需平衡周围正常结构损伤风险。
- 目前尚无脑肿瘤来源血液或脑脊液生物标志物用于常规临床实践。
核心结论
- MRgFUS破坏血脑屏障以增强脑肿瘤液体活检是未来管理脑肿瘤患者的有前景策略。
研究设计与样本
- 通过Medline/PubMed数据库和临床试验注册库对MRgFUS用于脑肿瘤液体活检进行文献综述。
主要发现
- 高强度MRgFUS可消融脑肿瘤和靶组织,但需平衡周围正常结构损伤风险。
- 低强度脉冲频率MRgFUS可短暂破坏血脑屏障,促进瘤内或脑实质内治疗药物递送,并可能增强脑肿瘤来源生物标志物检测。
临床怎么用
- MRgFUS破坏血脑屏障可能作为增强脑肿瘤液体活检的辅助手段,但尚未进入常规临床实践。
局限性
- 由于生物学特性和当前检测方法的限制,尚无脑肿瘤来源血液或脑脊液生物标志物用于常规临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite advances in modern medicine, brain tumor patients are still monitored purely by clinical evaluation and imaging. Traditionally, invasive strategies such as open or stereotactic biopsies have been used to confirm the etiology of clinical and imaging changes. Liquid biopsies can enable physicians to noninvasively analyze the evolution of a tumor and a patient's response to specific treatments. However, as a consequence of biology and the current limitations in detection methods, no blood or cerebrospinal fluid (CSF) brain tumor-derived biomarkers are used in routine clinical practice. Enhancing the presence of tumor biomarkers in blood and CSF via brain-blood barrier (BBB) disruption with MRI-guided focused ultrasound (MRgFUS) is a very compelling strategy for future management of brain tumor patients. METHODS: A literature review on MRgFUS-enabled brain tumor liquid biopsy was performed using Medline/Pubmed databases and clinical trial registries. RESULTS: The therapeutic applications of MRgFUS to target brain tumors have been under intense investigation. At high-intensity, MRgFUS can ablate brain tumors and target tissues, which needs to be balanced with the increased risk for damage to surrounding normal structures. At lower-intensity and pulsed-frequency, MRgFUS may be able to disrupt the BBB transiently. Thus, while facilitating intratumoral or parenchymal access to standard or novel therapeutics, BBB disruption with MRgFUS has opened the possibility of enhanced detection of brain tumor-derived biomarkers. CONCLUSIONS: In this review, we describe the concept of MRgFUS-enabled brain tumor liquid biopsy and present the available preclinical evidence, ongoing clinical trials, limitations, and future directions of this application.
引用
- Rincon-Torroella J, Khela H, Bettegowda A, et al. Biomarkers and focused ultrasound: the future of liquid biopsy for brain tumor patients. J Neurooncol. 2021. PMID: 34613580. doi:10.1007/s11060-021-03837-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。